CERE Cerevel Therapeutics Holdings
- 42.615
- +0.025+0.06%
Cerevel Therapeutics Holdings News
Cerevel Therapeutics Holdings Insiders Placed Bullish Bets Worth US$2.51m
Quite a few insiders have dramatically grown their holdings in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) over the past 12 months. An insider's optimism about the company's prospects is a posit
Cerevel (CERE.US), acquired by ABBV.US (ABBV.US), achieves key targets for advanced Parkinson's disease drugs
Cerevel Therapeutics announced Thursday that its once-a-day oral drug candidate for Parkinson's disease, tavapadon, has achieved key goals in a key phase 3 trial as a combination therapy.
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
Health care stocks were mixed pre-bell Thursday, with the iShares Biotechnology ETF (IBB) down 0.1% and the Health Care Select Sector SPDR Fund (XLV) 0.4% higher. Elevance Health (ELV) stock was up mo
AbbVie Buyout Cerevel Posts Late-stage Win for Parkinson's Disease Drug
Express News | Cerevel Therapeutics' Topline Results From Phase 3 TEMPO-3 Trial For Tavapadon For Parkinson's Disease, Met Primary Endpoint, Demonstrating Statistically Significant Increase In Total "On" Time Without Troublesome Dyskinesia Vs. Placebo
Express News | Cerevel Therapeutics Holdings Inc - Tavapadon Was Generally Well Tolerated
Express News | Cerevel: Statistically Significant Reduction in "off" Time, Key Secondary Endpoint, Observed for Tavapadon Treatment Arm
Express News | Cerevel Therapeutics Holdings Inc - Results From Tavapadon Phase 3 Monotherapy Trials (Tempo-1 and Tempo-2) Are Expected in Second Half of 2024
Express News | Cerevel Therapeutics Holdings Inc: Tavapadon Met Primary Endpoint in Pivotal Phase 3 Tempo-3 Adjunctive Trial
Express News | Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living With Parkinson’s Disease
AbbVie Slips After Revising Guidance to Reflect Earnings Impact
Cerevel Therapeutics Holdings(CERE.US) Director Sells US$2.12 Million in Common Stock
$Cerevel Therapeutics Holdings(CERE.US)$ Director COLES N ANTHONY sold 50,000 shares of Common Stock on Apr 1, 2024 at an average price of $42.3328 for a total value of $2.12 million.Source: Announcem
Form 144 | Cerevel Therapeutics Holdings(CERE.US) Director Proposes to Sell 2.11 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 1, $Cerevel Therapeutics Holdings(CERE.US)$ Director NEAVELLE ANTHONY COLES intends to sell 50,000 shares of its common stock on Apr 1, with a total market value of approxi
Cerevel Therapeutics Holdings(CERE.US) Director Sells US$2.05 Million in Common Stocks
$Cerevel Therapeutics Holdings(CERE.US)$ Director COLES N ANTHONY sold 50,000 shares of Common Stocks on Mar 4, 2024 at an average price of $41.011 for a total value of $2.05 million.Source: Announcem
Cerevel Therapeutics Holdings(CERE.US) Director Sells US$2.06 Million in Common Stocks
$Cerevel Therapeutics Holdings(CERE.US)$ Director COLES N ANTHONY sold 50,000 shares of Common Stocks on Feb 29, 2024 at an average price of $41.1578 for a total value of $2.06 million.Source: Announc
Market Chatter: AbbVie Plans $13 Billion Bond Sale to Fund Acquisitions
AbbVie (ABBV) is planning a $13 billion corporate bond sale to finance acquisitions of ImmunoGen and Cerevel Therapeutics Holdings (CERE), Bloomberg News reported, citing people with knowledge of the
Rumor has it that ABBV.US (ABBV.US) plans to sell at least $13 billion in bonds to finance mergers and acquisitions
The Zhitong Finance App learned that according to people familiar with the matter, ABBV.US (ABBV.US) is seeking to sell at least 13 billion US dollars of corporate bonds to fund its acquisition of ImmunoGen (IMGN.US) and Cerevel Therapeutics (CERE.US). The sale plan is expected to be announced as early as Thursday after a conference call with fixed income investors on Wednesday, according to people familiar with the matter. The scale of this release is subject to change and will be determined on the day of release. AbbVie did not immediately respond to requests for comment. According to reports, in December of last year, AbbVie announced two in a row
AbbVie Plans to Offer Senior Notes to Fund Immunogen, Cerevel Deals
Top Gap Ups and Downs on Tuesday: MA, MUFG, RIO and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
AbbVie CEO to Retire; COO Robert Michael Named Successor
AbbVie (ABBV) announced Tuesday that Richard Gonzalez will retire as chief executive in July, when Chief Operating Officer Robert Michael will take on the CEO role. Gonzalez has led AbbVie since the b
Analysis
Price Target
No Data
